Concepts (197)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Chest Pain | 25 | 2020 | 219 | 5.690 |
Why?
|
| Emergency Service, Hospital | 27 | 2020 | 490 | 3.760 |
Why?
|
| Acute Coronary Syndrome | 18 | 2020 | 203 | 3.460 |
Why?
|
| Myocardial Infarction | 18 | 2020 | 483 | 2.030 |
Why?
|
| Patient Discharge | 7 | 2019 | 204 | 1.440 |
Why?
|
| Cardiology Service, Hospital | 3 | 2015 | 22 | 1.240 |
Why?
|
| Risk Assessment | 16 | 2020 | 1460 | 1.170 |
Why?
|
| Electrocardiography | 16 | 2020 | 636 | 1.130 |
Why?
|
| Coronary Angiography | 8 | 2018 | 162 | 1.110 |
Why?
|
| Exercise Test | 5 | 2019 | 223 | 0.960 |
Why?
|
| Troponin | 10 | 2020 | 109 | 0.950 |
Why?
|
| Middle Aged | 39 | 2020 | 12125 | 0.920 |
Why?
|
| Coronary Artery Disease | 3 | 2018 | 413 | 0.780 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2013 | 1307 | 0.770 |
Why?
|
| Male | 42 | 2020 | 19641 | 0.750 |
Why?
|
| Female | 42 | 2020 | 20261 | 0.740 |
Why?
|
| Aged | 29 | 2020 | 10538 | 0.720 |
Why?
|
| Length of Stay | 5 | 2015 | 329 | 0.700 |
Why?
|
| Decision Support Techniques | 4 | 2020 | 133 | 0.680 |
Why?
|
| Inpatients | 3 | 2011 | 90 | 0.650 |
Why?
|
| Humans | 49 | 2020 | 32798 | 0.640 |
Why?
|
| Predictive Value of Tests | 11 | 2020 | 887 | 0.630 |
Why?
|
| Angina Pectoris | 2 | 2013 | 22 | 0.620 |
Why?
|
| Adult | 25 | 2020 | 9560 | 0.590 |
Why?
|
| Chemokine CCL2 | 1 | 2018 | 48 | 0.560 |
Why?
|
| Hospitalization | 7 | 2020 | 488 | 0.530 |
Why?
|
| Logistic Models | 9 | 2020 | 783 | 0.520 |
Why?
|
| Troponin C | 1 | 2017 | 9 | 0.520 |
Why?
|
| Observation | 2 | 2013 | 24 | 0.500 |
Why?
|
| Anticoagulants | 4 | 2011 | 136 | 0.490 |
Why?
|
| Critical Pathways | 4 | 2018 | 49 | 0.490 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2017 | 947 | 0.480 |
Why?
|
| Emergency Medicine | 2 | 2008 | 121 | 0.460 |
Why?
|
| Odds Ratio | 6 | 2020 | 467 | 0.450 |
Why?
|
| Retrospective Studies | 11 | 2019 | 3701 | 0.440 |
Why?
|
| North Carolina | 8 | 2020 | 1546 | 0.420 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2008 | 85 | 0.400 |
Why?
|
| Vasodilator Agents | 1 | 2013 | 59 | 0.390 |
Why?
|
| Emergency Treatment | 1 | 2013 | 41 | 0.390 |
Why?
|
| Sterol O-Acyltransferase | 1 | 2012 | 11 | 0.380 |
Why?
|
| Heart Diseases | 2 | 2011 | 116 | 0.380 |
Why?
|
| Triage | 2 | 2010 | 75 | 0.370 |
Why?
|
| Coronary Vessels | 1 | 2013 | 164 | 0.360 |
Why?
|
| Risk Factors | 9 | 2020 | 3974 | 0.360 |
Why?
|
| Myocardial Revascularization | 3 | 2018 | 41 | 0.360 |
Why?
|
| Time Factors | 8 | 2020 | 2183 | 0.360 |
Why?
|
| Prospective Studies | 10 | 2020 | 2327 | 0.350 |
Why?
|
| Hospital Costs | 1 | 2011 | 49 | 0.350 |
Why?
|
| Coronary Stenosis | 1 | 2011 | 28 | 0.350 |
Why?
|
| Health Expenditures | 1 | 2011 | 68 | 0.350 |
Why?
|
| Patient Admission | 1 | 2011 | 59 | 0.340 |
Why?
|
| Fibrinolytic Agents | 2 | 2008 | 69 | 0.330 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2007 | 63 | 0.330 |
Why?
|
| Registries | 7 | 2015 | 315 | 0.320 |
Why?
|
| Diagnosis, Differential | 5 | 2020 | 526 | 0.320 |
Why?
|
| Health Services | 1 | 2010 | 39 | 0.310 |
Why?
|
| Delivery of Health Care | 1 | 2011 | 166 | 0.310 |
Why?
|
| Peptide Fragments | 2 | 2009 | 403 | 0.310 |
Why?
|
| Pulmonary Embolism | 4 | 2011 | 51 | 0.310 |
Why?
|
| Research Support as Topic | 1 | 2008 | 26 | 0.290 |
Why?
|
| United States | 12 | 2020 | 4108 | 0.280 |
Why?
|
| Acute Disease | 8 | 2020 | 259 | 0.280 |
Why?
|
| Cohort Studies | 8 | 2018 | 1844 | 0.270 |
Why?
|
| Drug Utilization Review | 1 | 2007 | 18 | 0.270 |
Why?
|
| Reproducibility of Results | 6 | 2017 | 767 | 0.270 |
Why?
|
| Severity of Illness Index | 8 | 2018 | 881 | 0.260 |
Why?
|
| Biomedical Research | 1 | 2008 | 171 | 0.250 |
Why?
|
| Prognosis | 4 | 2015 | 1544 | 0.230 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2005 | 108 | 0.230 |
Why?
|
| Myocardial Ischemia | 2 | 2008 | 105 | 0.220 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 4 | 2008 | 30 | 0.210 |
Why?
|
| Postural Balance | 1 | 2016 | 180 | 0.210 |
Why?
|
| Craniocerebral Trauma | 2 | 2015 | 58 | 0.210 |
Why?
|
| Coronary Disease | 1 | 2005 | 214 | 0.210 |
Why?
|
| Decision Making | 3 | 2016 | 202 | 0.200 |
Why?
|
| Pesticides | 1 | 2016 | 196 | 0.200 |
Why?
|
| Heart Failure | 5 | 2010 | 695 | 0.200 |
Why?
|
| Occupational Exposure | 1 | 2016 | 231 | 0.200 |
Why?
|
| Emergency Medical Services | 2 | 2018 | 181 | 0.200 |
Why?
|
| Follow-Up Studies | 5 | 2020 | 2284 | 0.200 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 240 | 0.190 |
Why?
|
| Transients and Migrants | 1 | 2016 | 298 | 0.190 |
Why?
|
| Hispanic Americans | 2 | 2020 | 930 | 0.180 |
Why?
|
| Age Factors | 4 | 2018 | 1197 | 0.180 |
Why?
|
| Comorbidity | 3 | 2009 | 573 | 0.180 |
Why?
|
| Aged, 80 and over | 7 | 2013 | 4032 | 0.170 |
Why?
|
| Patient Readmission | 2 | 2013 | 134 | 0.160 |
Why?
|
| Mortality | 1 | 2020 | 124 | 0.160 |
Why?
|
| Sensitivity and Specificity | 4 | 2020 | 576 | 0.160 |
Why?
|
| Multicenter Studies as Topic | 3 | 2010 | 111 | 0.160 |
Why?
|
| Hemorrhage | 3 | 2015 | 107 | 0.150 |
Why?
|
| Pain Measurement | 2 | 2019 | 356 | 0.150 |
Why?
|
| Enoxaparin | 2 | 2009 | 21 | 0.150 |
Why?
|
| Clinical Trials as Topic | 3 | 2010 | 307 | 0.140 |
Why?
|
| Heparin | 2 | 2009 | 70 | 0.140 |
Why?
|
| Ethnic Groups | 1 | 2020 | 474 | 0.140 |
Why?
|
| Hospital Mortality | 3 | 2009 | 205 | 0.140 |
Why?
|
| Troponin T | 1 | 2018 | 92 | 0.130 |
Why?
|
| Diagnostic Imaging | 1 | 2016 | 97 | 0.120 |
Why?
|
| Incidence | 3 | 2016 | 1238 | 0.120 |
Why?
|
| Death | 1 | 2015 | 53 | 0.120 |
Why?
|
| Algorithms | 1 | 2018 | 511 | 0.120 |
Why?
|
| Echocardiography, Stress | 1 | 2015 | 23 | 0.110 |
Why?
|
| Spinal Cord Injuries | 1 | 2015 | 40 | 0.110 |
Why?
|
| Clinical Protocols | 1 | 2015 | 91 | 0.110 |
Why?
|
| Hypotension | 1 | 2015 | 48 | 0.110 |
Why?
|
| Confidence Intervals | 2 | 2011 | 148 | 0.100 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 2 | 2010 | 18 | 0.100 |
Why?
|
| Efficiency, Organizational | 1 | 2013 | 19 | 0.100 |
Why?
|
| Shock | 1 | 2013 | 32 | 0.100 |
Why?
|
| Sex Factors | 3 | 2020 | 675 | 0.100 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 1140 | 0.100 |
Why?
|
| Hirudins | 2 | 2009 | 19 | 0.100 |
Why?
|
| Forecasting | 2 | 2010 | 143 | 0.090 |
Why?
|
| Treatment Outcome | 3 | 2009 | 3438 | 0.090 |
Why?
|
| Mass Spectrometry | 1 | 2012 | 99 | 0.090 |
Why?
|
| Radionuclide Imaging | 1 | 2011 | 26 | 0.090 |
Why?
|
| Academic Medical Centers | 2 | 2010 | 162 | 0.090 |
Why?
|
| Recombinant Proteins | 2 | 2009 | 247 | 0.090 |
Why?
|
| Coronary Care Units | 1 | 2011 | 7 | 0.090 |
Why?
|
| Models, Economic | 1 | 2011 | 19 | 0.090 |
Why?
|
| Tomography, X-Ray | 1 | 2011 | 5 | 0.090 |
Why?
|
| Cost Savings | 1 | 2011 | 35 | 0.090 |
Why?
|
| Drug Costs | 1 | 2011 | 47 | 0.090 |
Why?
|
| Adenosine | 1 | 2011 | 59 | 0.090 |
Why?
|
| Dobutamine | 1 | 2011 | 55 | 0.090 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 764 | 0.090 |
Why?
|
| Echocardiography | 1 | 2011 | 182 | 0.080 |
Why?
|
| Myocardium | 1 | 2011 | 191 | 0.080 |
Why?
|
| Heart | 1 | 2011 | 185 | 0.080 |
Why?
|
| Linear Models | 1 | 2011 | 445 | 0.080 |
Why?
|
| Medical Audit | 1 | 2010 | 16 | 0.080 |
Why?
|
| Carbon Dioxide | 1 | 2010 | 39 | 0.080 |
Why?
|
| Costs and Cost Analysis | 1 | 2010 | 102 | 0.080 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2009 | 38 | 0.080 |
Why?
|
| Safety Management | 1 | 2010 | 38 | 0.080 |
Why?
|
| Venous Thromboembolism | 1 | 2010 | 28 | 0.080 |
Why?
|
| Oxygen | 1 | 2010 | 144 | 0.080 |
Why?
|
| Program Evaluation | 1 | 2010 | 181 | 0.070 |
Why?
|
| Information Services | 1 | 2009 | 14 | 0.070 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2009 | 72 | 0.070 |
Why?
|
| Chi-Square Distribution | 1 | 2009 | 292 | 0.070 |
Why?
|
| Coronary Thrombosis | 1 | 2008 | 14 | 0.070 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2008 | 29 | 0.070 |
Why?
|
| Dyspnea | 1 | 2008 | 33 | 0.070 |
Why?
|
| Ticlopidine | 1 | 2008 | 17 | 0.070 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2008 | 15 | 0.070 |
Why?
|
| Tyrosine | 1 | 2008 | 23 | 0.070 |
Why?
|
| Pyridines | 1 | 2008 | 74 | 0.070 |
Why?
|
| Aspirin | 1 | 2008 | 62 | 0.070 |
Why?
|
| Heart Conduction System | 1 | 2008 | 78 | 0.070 |
Why?
|
| Continuity of Patient Care | 1 | 2008 | 72 | 0.070 |
Why?
|
| Patient Selection | 2 | 2008 | 281 | 0.070 |
Why?
|
| Peptides | 1 | 2008 | 125 | 0.070 |
Why?
|
| Quality Indicators, Health Care | 1 | 2007 | 60 | 0.070 |
Why?
|
| Cross-Sectional Studies | 1 | 2011 | 1572 | 0.060 |
Why?
|
| Guideline Adherence | 1 | 2007 | 120 | 0.060 |
Why?
|
| Cause of Death | 1 | 2007 | 240 | 0.060 |
Why?
|
| Coronary Artery Bypass | 1 | 2007 | 111 | 0.060 |
Why?
|
| Recurrence | 1 | 2007 | 282 | 0.060 |
Why?
|
| Research Design | 1 | 2008 | 331 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 240 | 0.060 |
Why?
|
| Singapore | 1 | 2005 | 11 | 0.060 |
Why?
|
| Survival Rate | 2 | 2018 | 894 | 0.050 |
Why?
|
| Diagnostic Errors | 1 | 2004 | 43 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2007 | 412 | 0.050 |
Why?
|
| Injury Severity Score | 2 | 2015 | 111 | 0.050 |
Why?
|
| Adolescent | 4 | 2015 | 3638 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2016 | 876 | 0.050 |
Why?
|
| Prevalence | 1 | 2005 | 1002 | 0.050 |
Why?
|
| Infant | 2 | 2015 | 1083 | 0.040 |
Why?
|
| Child, Preschool | 2 | 2015 | 1282 | 0.040 |
Why?
|
| Point-of-Care Systems | 1 | 2020 | 46 | 0.040 |
Why?
|
| Child | 2 | 2015 | 2478 | 0.030 |
Why?
|
| European Continental Ancestry Group | 1 | 2020 | 1163 | 0.030 |
Why?
|
| Glasgow Coma Scale | 1 | 2015 | 28 | 0.030 |
Why?
|
| Trauma Centers | 1 | 2015 | 85 | 0.030 |
Why?
|
| African Americans | 1 | 2020 | 1424 | 0.030 |
Why?
|
| Age Distribution | 1 | 2013 | 201 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2015 | 694 | 0.020 |
Why?
|
| Wounds and Injuries | 1 | 2013 | 245 | 0.020 |
Why?
|
| Nitroglycerin | 1 | 2010 | 11 | 0.020 |
Why?
|
| Exhalation | 1 | 2010 | 3 | 0.020 |
Why?
|
| Capnography | 1 | 2010 | 9 | 0.020 |
Why?
|
| Tomography, Spiral Computed | 1 | 2010 | 19 | 0.020 |
Why?
|
| Radiography, Thoracic | 1 | 2010 | 44 | 0.020 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2009 | 23 | 0.020 |
Why?
|
| Observer Variation | 1 | 2009 | 96 | 0.020 |
Why?
|
| ROC Curve | 1 | 2010 | 168 | 0.020 |
Why?
|
| Disease Management | 1 | 2010 | 128 | 0.020 |
Why?
|
| Syndrome | 1 | 2009 | 74 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 126 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2007 | 563 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2007 | 682 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2005 | 486 | 0.010 |
Why?
|
| Cardiology | 1 | 2005 | 108 | 0.010 |
Why?
|
| Young Adult | 1 | 2010 | 2730 | 0.010 |
Why?
|